Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Venkatesh D. Handratta"'
Publikováno v:
Neurocase. 16:125-134
Chronic traumatic brain injury (CTBI) is associated with contact sports such as boxing. CTBI results from repetitive blows to the head rather than from a single impact. CTBI individuals present with motor symptoms (incoordination, spasticity, parkins
Autor:
Venkatesh D. Handratta, Jayesh Kamath
Publikováno v:
Expert Review of Neurotherapeutics. 8:1787-1797
Desvenlafaxine succinate (DVS) is the succinate salt monohydrate of O-desmethylvenlafaxine, an active metabolite of venlafaxine. DVS is a serotonin-norepinephrine reuptake inhibitor (SNRI) like venlafaxine, but exhibits a differential serotonergic an
Publikováno v:
Future Neurology. 2:361-371
Venlafaxine is a serotonin–norepinephrine-reuptake inhibitor (SNRI) with a well-established efficacy, safety and tolerability profile. Desvenlafaxine succinate is the succinate salt monohydrate of O-desmethylvenlafaxine, an active metabolite of ven
Autor:
Lalji K. Gediya, Vincent C. O. Njar, Rena Farquhar, Tadas S. Vasaitis, Ritesh Kataria, Yun Qiu, Pankaj Chopra, Zhiyong Guo, Angela Brodie, Donnell Newman, Venkatesh D. Handratta
Publikováno v:
Journal of Medicinal Chemistry. 48:2972-2984
New chemical entities, steroidal C-17 benzoazoles (5, 6, 9 and 10) and pyrazines (14 and 15) were rationally designed and synthesized. The key reaction for synthesis of the benzoazoles involved the nucleophilic vinylic "addition-elimination" substitu
Autor:
Nicol Macpherson, Danijela Jelovac, Olga Goloubeva, Brian J. Long, Apinya Thiantanawat, Venkatesh D. Handratta, Joseph Ragaz, Angela Brodie
Publikováno v:
JNCI Journal of the National Cancer Institute. 96:456-465
Background: The antiestrogen tamoxifen has potent activity against estrogen receptor–positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient s
Publikováno v:
Medical hypotheses. 77(2)
Publikováno v:
Cancer chemotherapy and pharmacology. 60(6)
Novel potent C-4 azolyl retinoic acid metabolism blocking agents (RAMBAs)-VN/14-1, VN/50-1, VN/66-1, VN/67-1, and VN/69-1, have been synthesized and investigated for their in vitro and in vivo effects against breast and prostate cancers. These RAMBAs
Publikováno v:
Cancer research. 65(12)
Blocking estrogen receptors with antiestrogens and blocking estrogen synthesis with aromatase inhibitors are two strategies currently being used for reducing the effect of estrogen in postmenopausal estrogen receptor–positive breast cancer patients
Autor:
Angela Brodie, Olga Goloubeva, Jyoti Patel, Vincent C. O. Njar, Lalji K. Gediya, Carlic Huynh, Dianne Robert Soprano, Ivo P. Nanne, Venkatesh D. Handratta, Omoshile O. Clement
Publikováno v:
Journal of medicinal chemistry. 47(27)
Novel retinoic acid metabolism blocking agents (RAMBAs) have been synthesized and characterized. The synthetic features include introduction of nucleophilic ligands at C-4 of all-trans-retinoic acid (ATRA) and 13-cis-retinoic acid, and modification o
Autor:
James N. Ingle, Luciana Macedo, Danijela Jelovac, Brian J. Long, Venkatesh D. Handratta, Angela M. H. Brodie, Olga Goloubeva
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(21)
Purpose: To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmeno